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ABSTRACT
The E2F family of transcription factors has import-
ant roles in cell cycle progression. E2F4 is an E2F
family member that has been proposed to be pri-
marily a repressor of transcription, but the scope
of its binding activity and functions in transcriptional
regulation is not fully known. We used ChIP
sequencing (ChIP-seq) to identify around 16000
E2F4 binding sites which potentially regulate 7346
downstream target genes with wide-ranging func-
tions in DNA repair, cell cycle regulation, apoptosis,
and other processes. While half of all E2F4 binding
sites (56%) occurred near transcription start sites
(TSSs),  20% of sites occurred more than 20kb
away from any annotated TSS. These distal sites
showed histone modifications suggesting that
E2F4 may function as a long-range regulator,
which we confirmed by functional experimental
assays on a subset. Overexpression of E2F4 and
its transcriptional cofactors of the retinoblastoma
(Rb) family and its binding partner DP-1 revealed
that E2F4 acts as an activator as well as a repressor.
E2F4 binding sites also occurred near regulatory
elements for miRNAs such as let-7a and mir-17,
suggestive of regulation of miRNAs by E2F4. Taken
together, our genome-wide analysis provided
evidence of versatile roles of E2F4 and insights
into its functions.
INTRODUCTION
The E2F transcription factor (TF) family is composed of
eight different proteins including E2F1, E2F2, E2F3a,
E2F3b (an isoform of E2F3) and E2F4–E2F8, which
play pivotal roles in cell cycle progression and
differentiation by activating or suppressing certain
classes of E2F responsive genes (1,2). E2Fs have been
classiﬁed as either activators (E2F1–E2F3) or repressors
(E2F4–E2F8) (3). Interestingly, it was recently discovered
that E2F1–E2F3 can switch from being activators to
repressors in differentiating cells (4). The expression
of E2F1–E2F3 is highly regulated during cell cycle pro-
gression whereas E2F4 and E2F5 are constitutively
expressed (3).
The activity of E2F4 is regulated by several mechanisms
such as sub-cellular localization, interactions with retino-
blastoma (RB) proteins, post-translational modiﬁcation
such as phosphorylation, and decreased translation
mediated by antisense transcripts (5,6). Unlike E2F1,
E2F4 does not have a nuclear localization signal (NLS)
and primarily exists in the cytoplasm during cell cycle pro-
gression. Upon cell cycle arrest, due to the depletion of
mitogenic stimuli, cells start to enter into G0, and cyto-
plasmic E2F4 forms heterodimers with a DP protein,
which facilitates the localization of E2F4 complexes into
the nucleus in a CRM1 mediated manner (7,8). Nuclear
localized E2F4 complexes occupy target promoters and
regulate diverse classes of genes which are involved in
cell cycle, DNA repair and apoptosis (9). Three pocket
proteins, pRB, p107/RBL1, and p130/RBL2, are critical
cofactors for the regulation of E2Fs, and the expression
levels of these pocket proteins change depending upon the
phase of the cell cycle (10). Because of these results, it is
believed that E2F4 is not involved in promoting cell cycle
progression; instead, along with RBL2, it has crucial roles
in mediating cell cycle arrest in G0. The binding of the
E2F4–RBL2 complex to E2F4 responsive promoters
triggers the recruitment of HDAC complexes or other
co-repressors, resulting in the repression of target gene
expression (3,11).
Other observations however are not consistent with the
view that E2F4 is exclusively a repressor of cell prolifer-
ation. Abnormal expression or mutation of E2F4 causes
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nant tumors. Transfection of E2F4 into non-transformed
cells induces the oncogenic activity of E2F4 (12). In
addition, E2F4 over-expressing transgenic mice develop
tumors, providing evidence for the oncogenic activity of
E2F4 (13). Mutated E2F4 has been reported in various
tumors such as colorectal carcinomas, endometrial
cancers, gastric adenocarcinomas, prostatic carcinomas,
and ulcerative colitis-associated neoplasms, further
emphasizing the important role E2F4 plays in tumorigen-
esis (12,14). The recent ﬁnding that E2F1–E2F3 can
switch roles from activators to repressors suggests that
the function of other members of this family of regulators
may be also be more malleable that previously thought
(4). In order to better understand the physiological roles
of E2F4 and reconstruct its regulatory network, it is es-
sential to identify genome-wide E2F4 targets and establish
how target promoters respond to it.
Several chromatin immunoprecipitation (ChIP)
followed by chip (ChIP-chip) experiments have been
performed on core-promoter arrays with quiescent and
continuously growing cells. These studies have led to the
identiﬁcation of several hundred E2F4 targets that are
involved in diverse functions such as cell cycle regulation,
DNA damage repair, apoptosis, mRNA processing,
ubiquitination, etc. (9,15). A recent ChIP-chip study of
E2F4 using tiled ENCODE arrays identiﬁed 187 E2F4
binding sites in 1% of the human genome in
lymphoblastoid cells (16), suggesting the possibility that
E2F4 may have more than 10000 binding sites across the
entire human genome. In addition, even though E2F4
showed a strong binding preference to promoters, some
E2F4 binding sites were discovered in non-promoter
regions. Without a comprehensive and unbiased
genome-wide target analysis of E2F4, it is difﬁcult to
evaluate its promoter binding preferences or gain a
complete understanding of its functions as a transcription
factor.
The recently developed ChIP followed by sequencing
(ChIP-seq) technique makes it possible to conduct a
genome-wide unbiased search for binding sites of TFs
(17–20). We used ChIP-seq to catalog E2F4 binding
sites across the genome in the human B-lymphoblastoid
cell line, GM06990. We discovered 16246 putative E2F4
binding sites distributed across promoters to coding and
non-coding regions, providing evidence to support diverse
roles of E2F4, which were not reported in previous
studies. Furthermore, gene expression proﬁling in
response to overexpression of E2F4 in the presence of its
cofactors showed that it can function as an activator as
well as a repressor of transcription.
MATERIALS AND METHODS
Cell culture
The lymphoblastoid (GM06990) cell line was purchased
from Coriell and cultured in RPMI medium containing
15% fetal bovine serum (FBS) and 1% antibiotics (peni-
cillin/streptomycin). In order to perform time course ChIP
experiments, cells were harvested every 24h for 5 days.
Serum starvation was achieved by washing cells cultured
for 72h three times with RPMI medium without FBS,
then adding low-serum RPMI medium containing 0.1%
FBS and then cultivating them for 2 days. For serum
activation, low serum medium was replaced with RPMI
containing 15% FBS. Cells were then cultivated and har-
vested at 3, 9 and 18h.
ChIP sequencing
ChIP assays were performed as described previously (21).
Brieﬂy, GM06990 cells cultured for 72h were cross-linked
with 1% formaldehyde and incubated for 7min at room
temperature. Formaldehyde was deactivated by the
addition of glycine (125mM ﬁnal concentration).
Sonicated cell lysate containing an average size of 500bp
DNA fragments was used for immunoprecipitation
to enrich E2F4-DNA complexes using an anti-E2F4
antibody (SC-1082X, Santa Cruz Biotech).
Immunoprecipitated DNA was sequenced using Illumina
sequencing technology (single end sequencing). Data from
this study is available at the Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/projects/geo/, GSE21488
and GSE21439).
Quantitative-PCR validation
Primer pairs for 42 targets and a negative control region
(Supplementary Table S1) for normalization were
designed using Primer3 (http://frodo.wi.mit.edu/primer3/
input.htm). Quantitative-PCR (qPCR) was performed
using the SYBR green PCR kit from Applied
Biosystems with 1ng of ChIP and input DNA. Fold en-
richment of targets in ChIP DNA relative to input was
calculated from an average of three replicate qPCR
reactions.
E2F4 overexpression and expression microarrays
Full length E2F4, DP-1 and RBL2 clones were purchased
from Open Biosystems and subcloned into the pcDNA 3.1
vector (Invitrogen). Either full-length expression con-
structs or empty vectors as a control were transfected
into HeLa cells using Lipofectamine 2000 from
Invitrogen. Total RNA was extracted from cells trans-
fected with combinations of the three factors (E2F4,
DP-1 and RBL2) or vector transfected cells using Trizol.
Microarray experiments were performed using spotted
HEEBO oligonucleotide human arrays (22), which has
44308 probes, using the protocol described previously
(23). Brieﬂy, total RNA was converted into cDNA and
labeled with Cy dyes (Cy3 for control and Cy5 for TF
overexpression). Dye-coupled cDNA was combined and
hybridized onto the oligo arrays for 14hr. Cy5/Cy3
ratios were calculated from scanned intensity data from
each channel. Data were normalized and analyzed by the
error model described previously (24).
TaqMan assay for miRNA expression
Total RNA was extracted from relevant samples by
Trizol. All primer sets for speciﬁc miRNAs and PCR
reagents for TaqMan miRNA assay were purchased
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formed using a 7900HT real time PCR machine from
Applied Biosystems. RNU66 was used as an internal
control for normalization. miRNA gene expression levels
relative to the control was calculated from an average of
four replicate qPCR reactions.
Luciferase reporter gene assay
Around 700bp of PCR-ampliﬁed insert from each of 10
distal binding sites was cloned into the upstream position
of a SV40 promoter in a pGL3 plasmid (Promega cat. #
E1761) between the KpnI and XhoI restriction sites. All
primers used for cloning are listed in Supplementary
Table S1. For the luciferase reporter gene assay, approxi-
mately 3 10
5 HEK 293 cells were co-transfected with
200ng of the pGL3 vector or reporter construct contain-
ing the Fireﬂy reporter gene as well as 10ng of pRL-PK
vector (Promega cat. # E2241) containing a Renilla
reporter gene, which served as an internal control
reporter, using 1ml of lipofectamine 2000 (Invitrogen)
and Opti-MEM medium (Invitrogen). After transfection
and incubation for 24h, cells were washed with PBS once,
lysed, and assayed to measure luciferase activity using the
Dual Luciferase assay Kit (Promega cat. # E1910) accord-
ing to manufacturer’s instructions. Fireﬂy luciferase
activity from the pGL3 construct was then normalized
to Renilla luciferase activity. To calculate relative expres-
sion fold change, ﬁreﬂy activity of the pGL3 vector con-
taining a distal E2F4 binding site were further normalized
with that of an empty pGL3 vector. P-value was
calculated from three independent transfections using a
t-test.
Identiﬁcation of ChIP-seq binding peaks and sites
Illumina sequencing generated 23–32 base pair short reads
from the ends of ChIP-enriched DNA fragments. These
short reads were mapped back to the genome using the
ELAND algorithm. We obtained 6508011 uniquely
aligning reads from the E2F4 chip library and 8474489
uniquely aligning reads from the input library. To identify
E2F4 binding sites from high-throughput Illumina
sequencing data, we used a Parzen window based algo-
rithm as described previously with minor modiﬁcations
(25). Each read was assigned a score that was essentially
the frequency of observing that read in the sequencing
library. The plus and the minus strand reads were
analyzed separately to ﬁnd peaks on the plus and minus
strands, respectively. The algorithm begins by assigning
the score of each read to its neighboring nucleotides as a
function of the read’s distance from that nucleotide. The
function used to assign scores was a Gaussian kernel with
a deﬁned band-width. Local maxima on the plus and
minus strands were deﬁned as peaks. High scoring plus
peaks that are upstream and within 500bp of minus
strand peaks were considered to be paired and the
distance between the paired plus and the minus peak
was calculated as the fragment length. A second iteration
of peak ﬁnding was then carried out, where all aligning
reads were extended in the 30 direction by half of the
previously estimated fragment length, to effectively repre-
sent the center of the ChIP fragment. The peak-ﬁnding
algorithm described above was used again on these pos-
itions to ﬁnd local maxima across the genome thereby
deﬁning binding sites. The score associated with the nu-
cleotide corresponding to the maxima was assigned to the
binding site.
Input correction
In order to correct high ChIP-seq scores arising from re-
petitive sequences or copy number repeats rather than true
ChIP enrichment, we normalized the E2F4 scores by the
parallel input sequencing scores. Scores for E2F4 peaks
that were within 500bp from any input peak were
divided by the corresponding input peak score. If a
given E2F4 peak overlapped with more than one input
peak, the higher scoring input peak was used for the cor-
rection. E2F4 peaks mapping to within 10000bp from any
transcription start site (TSS) of a gene were not input
corrected, since peaks near promoters in sonicated
crosslinked chromatin can arise even in input DNA due
to transcription factor binding (26). This restriction
applied to only a small fraction (1.3%) of all E2F4 sites
reported here.
False discovery rate
We ran the peak-ﬁnding algorithm on a set of randomly
simulated read coordinates equal in number to the
ChIP-seq data. These simulations were repeated 20
times. At each of a series of different score thresholds,
the number of E2F4 peaks found after input correction
was compared to those found in the random simulations
to give the false discovery rate (FDR).
Saturation
We used a capture–recapture analysis to estimate satur-
ation of binding sites in our E2F4 data. Capture-recapture
analysis has been used to estimate population sizes of
animals in a given area. The reads from the E2F4 chip
library were obtained in two sets or ‘lanes’, the ﬁrst set
having 2305280 reads and the second set having 4202731
reads. Each set was treated as an independent capture.
The entire genome was binned into 500bp bins and
reads mapping to each bin were counted for the two sets
separately. Each bin was now assigned a P-value value
dependent on the number of reads observed within that
bin according to a random Poisson model. At different
P-value thresholds, we calculated the following:
N1: number of bins in set 1;
N2: number of bins in set 2;
K: number of bins common to set 1 and set 2;
E1: expected number of bins in set 1 according to a
random Poisson model;
E2: expected number of bins in set 2 according to a
random Poisson model;
FDR1: (E1/N1) 100;
FDR2: (E2/N2) 100;
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tives at each enrichment cut-off.
The estimated number of E2F4 bins at each P-value
cut-off was calculated as:
P=(N1 E1) (N2 E2)/min[k(1 E1/N1), k(1 E2/N2)].
Whereas the observed number of bins was calculated as:
O=(N1 E1)+(N2 E2) min[k(1 E1/N1),
k(1 E2/N2)].
The percentage saturation was calculated as:
S=(O/P) 100.
For each P-value cut-off, we calculated the average
FDR as the geometric mean of FDR1 and FDR2. The
percentage saturation (S) was now plotted as a function
of the average FDR.
Mapping binding sites to gene features
To detect E2F4 target genes, E2F4 sites were mapped to
within 2kb from the TSS of all genes annotated in the
RefSeq database. In order to estimate the number of
sites mapping to different gene features, it was necessary
to assign one site to one and only one gene feature. Since
E2F4 has been known to preferentially bind near the TSSs
of genes, we used the following hierarchy to assign sites
to features: core>upstream>intron>exon>intergenic.
Core was deﬁned as 2000bp upstream and downstream
from the TSS, upstream was deﬁned as >2000bp
upstream to a maximum of 20000bp upstream from the
TSS. Binding sites that could not be mapped to within
20000bp upstream of any TSS and were not assigned
to any intron or exon were termed intergenic. Genes
that had E2F4 binding sites within the core were deﬁned
as targets.
Mapping binding sites to miRNAs
In order to identify miRNA targets of E2F4, we excluded
binding sites that mapped to core promoters, as it was not
possible to unequivocally assign such sites to the
annotated gene or the miRNA using binding data alone.
We included miR-22 as a special case for further charac-
terization because we have identiﬁed a role for miR-22 in
the cell cycle (A.A. Bhinge and V.R. Iyer, unpublished
data). Sites mapping to intergenic regions, introns and
exons were mapped to within 10000bp of the annotated
starts of mature miRNAs. The data for mature miRNA
start/stop coordinates was downloaded from miRBase
(www.mirbase.org).
Generating TSS/TTS proﬁles
A region of 20kb around the TSS (10kb upstream and
10kb downstream), was binned in 50bp size bins and
E2F4 sites were mapped to each bin. Each bin was
assigned the score of the peak that mapped to it.
Corresponding bin scores were averaged across all genes
to generate an average peak score proﬁle across the TSS.
This average proﬁle was smoothened by a moving window
of three bins. The same procedure was used to generate
transcription termination site (TTS) proﬁles.
Motif analysis
Since attempting to run motif discovery algorithms on all
binding sites would have been computationally expensive,
we divided the binding sites into strong (score  24.93),
moderate (scores 8.01–9.01) and weak (scores 5.6–5.75)
categories and considered the top 500 sites from each
category for motif discovery. A 200bp region centered
on each site was extracted from the human genome
assembly hg18. Motif discovery was performed using the
software DRIM (27) on each category separately at a
P-value threshold of 1 10
 5. A random background
was generated by sampling 200000 sequences of 200bp
from the genome. E2F4 sites (55.9%) occurred within
2kb upstream and downstream of TSSs of genes and
this ratio was maintained in the random sample. In
addition, we calculated the enrichment of each motif
with respect to the random background as a function of
the peak score. To analyze the relationship between each
motif and different gene features like core, upstream,
intron, exon and intergenic (as deﬁned above), we
divided sites into different features such that each site
was assigned to one and only one feature (as described
above) and then extracted sequences associated with
these feature-speciﬁc sites (200bp centered on the site).
Then, for each feature, we counted the number of sites
that had a given motif and divided this number by the
total number of sites that had that speciﬁc motif. This
was repeated for each of the ﬁve analyzed features for a
given motif and the data was displayed as a heat-map.
Motif co-enrichment
Conserved TF binding site data for the human genome
assembly hg18 was obtained from http://genome.ucsc.
edu. This data contains TF bind sites (TFBS) for 398
TFs from the TRANSFAC database that are conserved
between human, mouse and rat (http://genome.ucsc
.edu/cgi/bin/hgTrackUi?hgsid=118849564&c=chr13&-
g=tfbsConsSites). A TFBS was considered associated
with an E2F4 site if it was found within 250bp of that
site. The frequencies of TFBS associated with binding sites
were calculated for E2F4 peaks as well as for the
randomly generated peaks. The analysis was performed
on the strong, moderate, and weak categories separately
and P-values were calculated according to a binomial
model. We excluded TFBS that were not enriched at a
P-value of <1 10
 6 and were associated with less than
4% of the E2F4 sites under consideration.
Motif co-occurrence
We counted the number of different motifs that were
associated with each binding site peak (i.e. within 100bp
on either side of the peak), and compared the distribution
of these counts between randomly generated peaks and
E2F4 binding site peaks.
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Optimal cell culture conditions for E2F4 ChIP in
lymphoblastoid cells
Since E2F4 is thought to occupy its target promoters
in quiescent cells which could arise after long periods in
culture, we ﬁrst examined E2F4 ChIP efﬁciency in
lymphoblastoid cells that were grown for 24, 48, 72 and
96h after replating, and hybridizing the ChIP-enriched
DNA to a core-promoter array that covered from  750
to +200bp from the TSS of  9000 genes. We also
investigated E2F4 binding to its target promoters in
serum-starved and serum-fed cells using core promoter
arrays because it is known that upon serum starvation,
E2F4 accumulates in the nucleus and is recruited to its
target promoters, resulting in cell cycle arrest (28).
Strong occupancy signals for E2F4 were detected at 72h
and were maintained at 96h. We found that the E2F4
binding proﬁle was not signiﬁcantly affected by serum-
starvation or stimulation in lymphoblastoid cells
(Supplementary Figure S1). Based on the above results,
we generated ChIP-seq data for E2F4 in lymphoblastoid
cells that were maintained in culture for 72h.
Identiﬁcation and veriﬁcation of E2F4 binding sites from
ChIP-seq data
Illumina sequencing of E2F4 ChIP generated around
6.5-million sequence reads that uniquely mapped to the
reference human genome sequence. In order to identify
E2F4 binding sites from this data, we developed a peak
detection program using a Parzen windows density esti-
mation algorithm we have previously used to map nucleo-
some positions (25). We also sequenced a parallel sample
of input DNA from the same cells as a control to ensure
that enriched sites were not an artifact of the processing
and sequencing. Our algorithm identiﬁes discrete regions
of  150bp around each ChIP-seq peak which we refer to
as sites. Known E2F4 targets were easily detected in our
ChIP-seq data (Figure 1A). We observed that some strong
peaks in the ChIP dataset corresponded to equally
strong peaks in the input sequencing data (Figure 1B).
Such peaks may arise due to the presence of repeat
regions in the genome and are thus false positives. To
minimize such false positive targets, we ﬁrst normalized
the ChIP peaks by dividing the ChIP peak scores with
their corresponding input peak scores. Next, we calculated
a FDR based on random simulations to decide an appro-
priate signiﬁcance threshold (Figure 1C). At 1% FDR,
which corresponded to an input-corrected peak score of
4.4, we identiﬁed 16246 putative E2F4 binding sites across
the entire genome (Supplementary Table S2). To verify the
quality of the putative E2F4 binding sites, we investigated
overlaps between ChIP-seq targets with those from our
core promoter arrays. Around 84% of core promoter
targets were also found in the ChIP-seq data
(Supplementary Figure S2). As further veriﬁcation, we
assayed 42 randomly selected targets by quantitative-
PCR (qPCR), including 30 targets with a score between
4.4 and 8, as well as 12 targets with a score <4.4, which
was below our 1% FDR threshold. Overall, binding sites
with stronger ChIP-seq scores showed higher fold enrich-
ment by qPCR. Speciﬁcally, more than 90% of the targets
above the 1% FDR threshold showed an enrichment of at
least 1.5-fold by qPCR. On the other hand, only 41% of
sites below the 1% FDR threshold showed enrichment by
qPCR (Figure 1D). We also estimated the extent to which
we identiﬁed all E2F4 sites in the genome, using a
tagging-recapture saturation analysis (see Materials and
Methods section). At the FDR threshold of 1% and our
given sequencing depth, we estimated that we identiﬁed
more than 80% of all E2F4 binding sites in the human
genome in lymphoblastoid cells (Figure 1E).
Distribution of E2F4 binding sites in relation to gene
annotations
We ﬁrst examined the relationship of E2F4 binding with
the distribution of genes. E2F4 binding sites are correlated
well with gene density across the genome (r
2=0.75)
(Figure 2A). Next, we investigated the distribution of
E2F4 binding sites across ﬁve different categories of
genomic elements including promoter, exon, intron,
intergenic and upstream regions by mapping E2F4 sites
relative to RefSeq annotated genes. Approximately 56%
of the sites occurred within promoters (Figure 2B). In
addition, the binding proﬁle of E2F4 around TSSs also
provided evidence that E2F4 had a preference for binding
promoters, especially near the TSS, whereas no signiﬁcant
binding preference was observed near the TTSs
(Figure 2C). This result is consistent with previous
studies using selective arrays, showing that the binding
sites of several TFs, including E2F1, were mainly
distributed near the TSSs (16,29,30) Since E2F4 showed
preferential binding at promoters, we examined whether
the binding strength as measured by the peak score of
E2F4 sites at promoters was stronger than sites at other
genomic regions. E2F4 promoter sites showed signiﬁ-
cantly higher peak scores compared to those from other
genomic regions (Figure 2D). Taken together, these results
show that not only does E2F4 bind preferentially to
promoters, but it also binds with higher occupancy
to promoters as compared to other genomic regions.
E2F4 and bidirectional promoters
It has been reported that consensus E2F4 motifs are sig-
niﬁcantly overrepresented in bidirectional promoters (31).
Approximately 11% of all genes have been reported to
have bidirectional promoters in mammalian genomes
(32,33). For our analysis, we ﬁrst deﬁned bidirectional
promoters as the region of DNA between the TSSs of
two genes that were divergently transcribed from
opposite strands and separated by <2kb. Based on this
criterion, we identiﬁed 918 bidirectional promoters corres-
ponding to 1836 genes among all the 18693 human genes
annotated in RefSeq. We then investigated whether E2F4
binding sites showed a bias toward binding to bidirec-
tional promoters. Of the 4599 E2F4 target genes where
its binding site was within the same speciﬁed distance
(2kb) from the TSS, 572 were bidirectionally transcribed,
which was a signiﬁcant enrichment over background
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S3), indicating that many divergently transcribed genes
in the genome might be co-regulated by E2F4.
Divergently transcribed E2F4 target genes were highly
overrepresented in the categories of RNA processing,
DNA repair, protein folding and cell cycle.
Distal E2F4 sites could be enhancers or other regulatory
elements
In addition to strong promoter occupancy and bidirec-
tional promoter enrichment of E2F4 binding sites, a pro-
portion of E2F4 sites were also detected in introns (7.8%),
upstream regions (13.2%) and intergenic regions (21.7%)
(Figure 2B). Previous approaches have not identiﬁed this
latter class of E2F4 sites that are not at the core promoter.
To exclude the possibility that the limited number of TSS
annotated in Refseq ( 18000) was resulting in an over-
estimate of the number of intergenic binding sites, we
mapped all E2F4 sites to an expanded data set of
 60000 TSSs derived by combining RefFlat annotated
genes with additional gene annotations obtained from
the UCSC table browser (http://genome.ucsc.edu/cgi-
bin/hgTables) and further ﬁltered to remove redundant
TSS coordinates. Even with the much larger number of
TSSs used in this analysis, the number of intergenic E2F4
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Figure 1. E2F4 ChIP-seq reveals genome-wide E2F4 binding sites. (A) An example of a known E2F4 binding site that was identiﬁed in our ChIP-seq
data. Chromosome coordinates are indicated on top. The plot in the middle shows the density of ChIP-seq reads, with the peak score indicated on
the Y axis. The bottom track shows the CDC25C gene with coding regions, exons and introns indicated by thick or thin boxes and line, respectively.
The direction of transcription is indicated by the arrows from right to left. (B) An example of strong peaks discovered in both input and ChIP likely
due to copy number differences between the cell genome and the reference sequence. Such sites were removed by input correction (‘Materials and
Methods’ section). (C) FDR calculation based on random simulations. The 1% FDR threshold was used for further analysis. (D) qPCR veriﬁcation
of 42 randomly selected targets identiﬁed by ChIP-seq. Blue diamonds represent targets which passed the 1% FDR ChIP-seq threshold, and red
squares represent targets below this threshold. (E) Capture-recapture analysis to estimate saturation for E2F4 targets (see Methods). x-axis represents
 log10 FDR and the y-axis shows the saturation as a percentage of expected sites that were discovered at each FDR.
Nucleic Acids Research,2011, Vol.39, No. 9 3563sites showed only a modest decrease from 22.5 to 17.5%,
indicating that a signiﬁcant proportion of E2F4 sites are
truly intergenic. We then analyzed the distribution of
E2F4 sites at different peak score cut-offs to investigate
whether the percentage of intergenic sites was dependent
on the score. Although the proportion of intergenic sites
decreased with an increase in the score threshold, it
remained fairly constant above a score cut-off of 10,
where  10% of E2F4 sites were deemed intergenic
(Figure 2E). Overall, these results indicate the existence
of a signiﬁcant number of strong E2F4 sites that were
found <20kb away from any annotated TSS.
It is well-established that TFs are able to regulate the
expression of target genes by binding to promoters or
long-range regulatory elements such as enhancers and in-
sulators. To investigate the possibility that some of the
distal (upstream and intergenic) E2F4 binding sites repre-
sent enhancers, we examined these distal E2F4 binding
sites (based on the expanded TSS annotations above) for
the presence of characteristic enhancer signature marks
based on published histone modiﬁcation data (17,34,35).
Genome-wide histone signature analyses have revealed
that the three forms of H3K4 methylation (H3K4me1,
H3K4me2 and H3K4me3), H3K9me1, H3K18ac and the
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Figure 2. The genome-wide distribution pattern of E2F4 binding sites. (A) The correlation between E2F4 binding sites and gene density. Each point
on the plot represents a 20Mb bin. (B) A pie chart representation of the distribution of E2F4 binding sites in ﬁve different genomic regions. The
deﬁnition of each genomic region is described below. Core promoters are within ±2kb from the TSS, upstream is from 2 to 20kb upstream from the
TSS, and intergenic is a region not included as a promoter, upstream region, intron or exon. (C) Distribution of E2F4 binding sites within ±10kb.
Inset shows a close up of a 1kb region centered on the TSS. (D) A box-plot shows the ChIP-seq peak score distribution across ﬁve different genomic
regions. Peak scores in core promoters were signiﬁcantly higher compared to those from other genomic regions (P<5.5 10
 15, Wilcoxon test with
Bonferroni correction). (E) Distribution of E2F4 binding sites depending on peak scores. Even though the number of intergenic sites decreased with
increasing score, a substantial proportion of intergenic sites (10%) still remained at a score of 10.
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found that 36% of the intergenic E2F4 binding sites and
68% of the upstream sites had at least one histone
enhancer marker, with most of these E2F4 sites showing
multiple enhancer makers (Figure 3A). To verify the pos-
sibility that distal E2F4 binding sites could function as
enhancers, we ﬁrst tested whether they showed binding
by p300, a known marker of enhancers in mammalian
cells (36). We tested p300 binding at 10 randomly
selected distal E2F4 enhancer candidate sites using ChIP
followed by real-time PCR. We found that 9 out of 10 sites
showed signiﬁcant binding by p300 (Supplementary
Figure S3), which supported the possibility that some of
the distal E2F4 binding sites we identiﬁed by ChIP-seq
could function as enhancers. To functionally test this pos-
sibility further, we cloned these 10 candidates into pGL3
promoter-containing enhancer reporter vectors and per-
formed luciferase reporter gene assays. Five of the 10
sites conferred signiﬁcant increase in expression of their
reporter genes (P<0.005) at levels comparable to or
greater than a positive control enhancer, conﬁrming that
a subset of distal E2F4 binding sites could indeed function
as enhancers (Figure 3B). Based on the reporter assays, we
can estimate that  1048 out of 4147 distal E2F4 binding
sites may function as enhancers. Distal E2F4 sites that did
not show any enhancer marks may potentially regulate
non-coding genes such as miRNAs whose promoters are
not well deﬁned, or these distal sites could be transcrip-
tionally neutral.
Putative E2F4 target genes are involved in a broad range
of biological processes
In order to investigate the functions of E2F4 suggested by
its genome-wide binding proﬁle, we ﬁrst considered all
E2F4 sites that occurred within ±2kb from the TSS of
all genes annotated in the RefSeq database. We found
7346 genes that had E2F4 binding sites in their promoters,
which cover  30% of all annotated human genes
(Supplementary Table S4). Next, we analyzed functional
categories among these putative E2F4 target genes using
the database for annotation, visualization and integrated
discovery (DAVID) (37). In agreement with previously
reported results, E2F4 target genes were highly enriched
for cell cycle, DNA repair, RNA processing, stress
response, apoptosis and ubiquitination (Table 1). We
also found signiﬁcant enrichment among E2F4 targets
for additional functions that have not previously been
associated with E2F4, such as protein transport and tar-
geting, protein folding and I-kappaB kinase/NF-kappaB
cascade. KEGG pathway analysis also showed strong
enrichment of E2F4 in the categories of cell cycle,
ubiquitin-mediated proteolysis, p53 signaling pathway
and chronic myeloid leukemia (Supplementary
Table S5). We also found that E2F4 binds to the pro-
moters of 780 TFs out of the approximately 2000 known
TFs in the human genome (Supplementary Table S6),
which suggests that E2F4 regulates broad classes of
genes indirectly. Taken together, these results suggest
that E2F4 could regulate more diverse biological processes
than previously suspected.
E2F4 potentially regulates other E2F family members
and its cofactors
Previous ChIP-chip studies have revealed that members of
the E2F family transcriptionally regulate each other
(9,29). For instance, E2F4 occupies the promoters of ac-
tivator E2Fs (E2F1, E2F2 and E2F3) and represses their
expression to cause cell-cycle arrest. We found that E2F4
occupied the promoters of all E2F family genes including
E2F7 and E2F8, which are RB independent repressors (2).
The notable exceptions were E2F4 itself, and E2F6
(Supplementary Table S7), which interestingly, functions
redundantly with E2F4 as a repressor. E2F4 also occupied
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Figure 3. Some E2F4-bound distal sites function as enhancers.
(A) Relationship of histone enhancer marks with the 2857 intergenic
E2F4 sites (a) or 1560 upstream E2F4 sites (b). Data for histone modi-
ﬁcations indicative of enhancers was obtained from previous studies
(17,35), assigned to E2F4 binding sites identiﬁed here and hierarchically
clustered for display. The relative strength of the histone modiﬁcation
signal is indicated in the heat-map according to the color table.
Sixty-eight percent of upstream and 36% of intergenic E2F4 sites con-
tained at least one enhancer mark. (B) Luciferase reporter gene assays
for randomly chosen 10 distal E2F4 binding sites. The y-axis represents
the expression fold change of a luciferase reporter gene normalized to
an empty-vector control. P-values were calculated using t-test from
three independent transfections. E1 through E10 represent 10
enhancer candidates randomly selected from among distal E2F4
binding sites. ‘P’ represents a positive control enhancer selected based
on a previously published study (64). Single and double asterisks indi-
cates P<0.005 and 0.001, respectively.
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RBL1 and p130/RBL2), and two binding partners (DP1
and DP2). In particular, E2F4 showed strong binding at
the promoters of E2F1–E2F3, which are genes involved in
cell cycle progression. To identify targets that were
common to E2F1 and E2F4, we compared our E2F4
targets with previously published E2F1 targets obtained
from ChIP-chip data in the same cell line (16). Among the
top 2000 known E2F1 targets, 1416 targets ( 70%)
overlapped with our E2F4 targets identiﬁed by ChIP-seq
(Supplementary Table S8). Functional analysis revealed
that cell cycle and DNA repair functions were highly
enriched among these genes that were occupied by both
E2F1 and E2F4.
The RB protein family has important roles in the regu-
lation of E2F activity. Several studies have showed that
E2F4 can form a complex with one of three RB proteins,
and that the abundance of the E2F4-RB complex varies
depending on the cell cycle state (8,15). We compared the
overlap of our E2F4 targets with previously known RBL1
and RBL2 targets identiﬁed by ChIP-chip using a
core-promoter array of 14000 genes (9). We found that
 87% of previously identiﬁed RBL1 and RBL2 targets
were also bound by E2F4 in our ChIP-seq data.
Table 1. Functional categories of E2F4 target genes
Biological functions Count (Percent) Fold enrichment P-value FDR
Biopolymer metabolic process 2259 (34.81) 1.36 6.32E-103 1.21E-99
Nucleotide and nucleic acid metabolic Process 1736 (26.75) 1.38 1.86E-77 3.57E-74
Cell cycle 490 (7.55) 1.77 8.05E-52 1.54E-48
Gene expression 1499 (23.10) 1.31 2.09E-46 4.00E-43
RNA processing 277 (4.27) 1.96 1.55E-39 2.97E-36
Organelle organization and biogenesis 579 (8.92) 1.57 3.36E-39 6.42E-36
Response to DNA damage stimulus 208 (3.21) 2.07 7.92E-35 1.51E-31
Biopolymer modiﬁcation 811 (12.50) 1.4 1.06E-32 2.03E-29
mRNA processing 172 (2.65) 2.14 3.14E-31 6.01E-28
RNA splicing 156 (2.40) 2.22 3.23E-31 6.18E-28
Protein modiﬁcation process 772 (11.90) 1.38 1.98E-29 3.78E-26
DNA repair 171 (2.64) 2.07 1.48E-28 2.83E-25
Ubiquitin cycle 278 (4.28) 1.74 7.46E-28 1.43E-24
Response to endogenous stimulus 230 (3.54) 1.84 1.38E-27 2.64E-24
Macromolecule localization 401 (6.18) 1.54 2.09E-25 4.00E-22
Protein transport 345 (5.32) 1.6 2.64E-25 5.05E-22
Chromosome organization and biogenesis 221 (3.41) 1.81 3.61E-25 6.91E-22
Post-translational protein modiﬁcation 653 (10.06) 1.39 4.68E-25 8.96E-22
Transcription 1061 (16.35) 1.27 1.67E-24 3.19E-21
Protein localization 373 (5.75) 1.53 1.34E-22 2.56E-19
DNA replication 145 (2.23) 1.87 1.42E-18 2.73E-15
Apoptosis 356 (5.49) 1.47 3.15E-18 6.02E-15
Chromatin modiﬁcation 118 (1.82) 1.9 1.11E-15 2.12E-12
Establishment and maintenance of Chromatin 165 (2.54) 1.69 4.09E-15 7.86E-12
DNA packaging 166 (2.56) 1.67 1.48E-14 2.85E-11
Chromosome segregation 50 (0.77) 2.56 2.65E-14 5.05E-11
Ribonucleoprotein complex biogenesis and assembly 116 (1.79) 1.85 2.84E-14 5.44E-11
Protein targeting 122 (1.88) 1.8 7.12E-14 1.36E-10
Cell development 489 (7.54) 1.27 1.16E-10 2.21E-07
RNA localization 58 (0.89) 2.1 1.36E-10 2.61E-07
Protein modiﬁcation by small protein conjugation 55 (0.85) 2.14 1.73E-10 3.30E-07
Sister chromatid segregation 28 (0.43) 2.82 6.29E-10 1.20E-06
Protein ubiquitination 51 (0.79) 2.11 1.76E-09 3.37E-06
Ubiquitin-dependent protein catabolic process 98 (1.51) 1.68 3.04E-09 5.81E-06
Ribosome biogenesis and assembly 55 (0.85) 1.95 2.16E-08 4.14E-05
Protein kinase cascade 174 (2.68) 1.43 2.96E-08 5.67E-05
Response to stress 416 (6.41) 1.24 6.16E-08 1.18E-04
Spindle organization and biogenesis 19 (0.29) 3.06 6.67E-08 1.28E-04
Phosphate metabolic process 399 (6.15) 1.25 1.07E-07 2.04E-04
Phosphorus metabolic process 399 (6.15) 1.25 1.07E-07 2.04E-04
Protein folding 127 (1.96) 1.49 2.01E-07 3.85E-04
DNA damage response, signal transduction 33 (0.51) 2.22 3.98E-07 7.62E-04
Protein–RNA complex assembly 62 (0.96) 1.73 1.07E-06 0.002
Regulation of gene expression, epigenetic 34 (0.52) 2.11 1.43E-06 0.002
Chromatin assembly or disassembly 73 (1.12) 1.63 2.06E-06 0.003
Lipid biosynthetic process 124 (1.91) 1.44 2.09E-06 0.004
Microtubule organization and biogenesis 17 (0.26) 2.89 2.53E-06 0.004
Centrosome organization and biogenesis 17 (0.26) 2.89 2.53E-06 0.004
I-kappaB kinase/NF-kappaB cascade 69 (1.06) 1.63 3.98E-06 0.007
Count represents the number of genes in the biological function category. Percent shows the proportion of E2F4 targets among the count. FDR is
the false discovery rate. Functional categories were as deﬁned by the online database DAVID (37). P-values and FDR were also as calculated using
their online tool, based on the list of E2F4 target genes identiﬁed in this study.
3566 Nucleic Acids Research, 2011,Vol.39, No. 9Additionally, we found that 75% of genes previously
reported as being bound RBL1 alone were in fact
occupied by E2F4 in our dataset, and the majority of
the remaining 25% of ‘RBL1-alone’ targets contained
E2F4 sites in their promoters that were just below our
1% FDR threshold. This suggests that almost all RBL1/
p107 and RBL2/p130 targets are in fact also occupied by
E2F4 (Supplementary Table S9).
Motif analysis of E2F4 binding sites
E2F family proteins bind to DNA as a heterodimeric
E2F-DP complex to the motif TTTc/gGCGCc/g (38).
We examined the presence of the consensus E2F motif
(TTTSSCGC) over all E2F4 binding sites identiﬁed by
ChIP-seq. Interestingly, we found that only 5% of E2F4
sites contained the consensus motif, suggesting that E2F4
might be recruited to its sites either through a novel motif
or via interaction with other proteins. In order to discover
alternative E2F4 motifs, we performed a de novo motif
search using the discovering rank imbalanced motifs
(DRIM) algorithm (27). We ﬁrst classiﬁed E2F4 sites
into three different groups, namely strong, moderate and
weak, based on binding strength. Next, we extracted the
top 500 sites from each group and then executed DRIM
on each set separately. We found a total of ﬁve different
motifs that were signiﬁcantly enriched over background
(P<1 10
 5) (Figure 4A). Of these, Motifs 2 and 3
were similar to motifs recently identiﬁed using microarray
based in vitro binding experiments for mouse E2F2 and
E2F3 (39). To investigate motif occurrence and enrich-
ment, and their dependence on binding strength, we
A
B
D
C
Figure 4. E2F4 motif analysis. (A) Enrichment of indicated motifs over background is plotted on the Y axis, as a function of ChIP-seq peak score
plotted on the x-axis. (B) Distribution of motifs around E2F4 binding sites identiﬁed by ChIP-seq. E2F4 motifs were mapped to E2F4 binding sites
and the distance of the identiﬁed motif from the maxima of the binding site was plotted as a histogram. The y-axis shows the percentage of peaks
that had an E2F4 motif within the speciﬁed distance shown on the x-axis. The ﬁgure indicates that the majority of E2F4 peaks had an E2F4 motif
within 20bp of the indicated nucleotide that was designated as the binding site. (C) Frequency of motif occurrence in ﬁve different genomic regions.
The heat-map shows the percentage distribution of E2F4 binding sites found in each genomic region for each of the six different E2F4 motifs used in
this study. E2F4 motifs 1–5 were found predominantly in sites that mapped to the core promoter except motif 6. Motif 6 was found at almost equal
frequency in sites that mapped to the core and intergenic regions. Color bar indicates percentage of a motif in a given genomic region. For a given
motif, the sum of the percentages across all ﬁve different genomic regions is 100%. (D) Number of motifs discovered within E2F4 sites segregated by
their ChIP-seq score. The density plot shows the relative frequency of sites on the y-axis containing each indicated number of motifs on the x-axis.
Sites with stronger ChIP-seq scores had more motifs and overall, E2F4 sites had approximately two motifs per site on average.
Nucleic Acids Research,2011, Vol.39, No. 9 3567mapped all six motifs (one canonical and ﬁve newly dis-
covered) back to all E2F4 sites. Figure 4A represents the
enrichment of each motif over background as a function
of ChIP-seq peak score. The canonical motif (motif 1) and
motif 2 showed the strongest enrichment over background
indicating that these two motifs correspond to high occu-
pancy E2F4 binding sites. Motifs 3 and 4 showed
moderate enrichment, and motifs 5 and 6 showed weak
enrichment over background. All motifs except motif 4
showed a gradual increase in the enrichment as well as
in the percentage prevalence amongst binding sites as a
function of peak score. Motif 4 hit the highest enrichment
around score 10 and showed an apparent decrease of en-
richment over background at higher ChIP-seq peak
scores. This was mainly because only a small number of
high-scoring E2F4 sites had this motif. Additionally, we
found that for most binding sites, at least one of the six
different E2F4 motifs was found <20bp from our
estimated peak position (Figure 4B).
To investigate whether different motifs are used to
recruit E2F4 to different genomic regions, we examined
the percentage occurrence of all six motifs at ﬁve different
genomic regions (promoters, upstream, intergenic, introns
and exons) to investigate any regional binding bias of each
motif. Most motifs, with the exception of motif 6, were
highly overrepresented in promoters, consistent with the
occurrence and scores of peaks in these ﬁve genomic
regions (Figure 2B and D). Motif 6 was distinct in that
it showed comparable enrichment in promoters and
intergenic regions as well as in introns, but not in
upstream and exons (Figure 4C), suggesting that motif 6
may have distinct regulatory roles in intergenic and
intronic regions. We also examined the number of motifs
within each binding site. On average, each E2F4 site con-
tained two motifs, while sites with higher scores contained
more than two motifs (Figure 4D), suggesting the possi-
bility of either multiple E2F4 DNA interactions per regu-
latory region, or usage of distinct motifs under different
physiological conditions. In order to investigate whether
speciﬁc binding motifs were associated with speciﬁc func-
tions, we grouped genes based on the presence of speciﬁc
motifs in their promoters and performed KEGG pathway
analysis for each group (Table 2). All E2F4 motifs were
used to regulate the cell cycle pathway and most motifs
were used in several different pathways. However, we
found that some pathways were signiﬁcantly enriched
with only one motif. For instance, motif 2 was
overrepresented in the biosynthesis of steroids pathway
while motif 3 was enriched in the N-glycan biosynthesis
pathway, and motif 4 in the chronic myeloid leukemia
pathway. Additionally, we found that motif 6 was
associated exclusively with cell cycle genes. These results
suggest that E2F4 may use distinct motifs to perform
speciﬁc physiological functions. We found several other
TF motifs to be signiﬁcantly co-enriched within 500bp
of E2F4 binding sites (Supplementary Table S10).
Among them, 10 TFs (EGR1-3, ELK1, PAX5, RFX1,
SP1, STAT1, RFX1 and YY1) were also targets of
E2F4 in our ChIP-seq data. Many cell cycle progression-
related TFs such as AP1, MAZ, ELK1 were also highly
enriched in the neighborhood of E2F4 binding sites and
such TFs may regulate genes along with E2F4 in a com-
binatorial or competitive manner.
Overexpression of E2F4 and its cofactors reveal that
E2F4 functions as an activator and a repressor
It has been reported that siRNA-mediated E2F4
knock-down leads to drug- or irradiation-induced apop-
tosis (3) while E2F4 knock-down in T98G cells does not
affect gene expression due to its functional redundancy
with E2F5 and E2F6 (9). In order to identify genes
whose expression levels are affected by E2F4 and
address whether E2F4 functions as an activator or a re-
pressor, we perturbed E2F4 expression levels by transient
overexpression and analyzed gene expression using micro-
arrays. We initially tried overexpressing E2F4 in
lymphoblastoid cells; however, the transfection efﬁciency
was too low to discriminate overexpression effects given
the background of untransfected cells. We therefore used
HeLa cells for gene expression proﬁling. Before perform-
ing overexpression experiments, we compared our E2F4
binding targets from lymphoblastoid cells with targets
from HeLa cells obtained from previously published
data (16) to conﬁrm that E2F4 binding proﬁles were com-
parable between the two cell lines. About 81% of the
E2F4 targets from HeLa cells were also found in
lymphoblastoid cells (Supplementary Figure S4), justify-
ing the use of HeLa cells to assay the effects of E2F4
overexpression. Transient overexpression of E2F4 alone
did not trigger dramatic expression changes, even
though some E2F4 responsive genes were up- or down-
regulated. This result is likely due to low levels of its co-
factors, which are required for E2F4 localization and
binding. We therefore performed expression proﬁling
after co-transfecting E2F4 with its cofactors (DP-1 and
RBL2). Co-transfection resulted in increased levels of
mRNA and protein for E2F4 and its cofactors
(Figure 5A and B). We performed at least two biological
replicates of the expression arrays and used an
error-model to identify statistically signiﬁcant genes
whose expression was altered in response to
overexpression of the regulators (24). Compared to
overexpression of E2F4 alone, co-transfection of E2F4
and its cofactors increased the number of targets that
showed signiﬁcant expression changes (Table 3 and
Supplementary Table S11). Overall, combinatorial
Table 2. Motif usage of E2F4 within different biological pathways
KEGG pathway terms Motifs
Cell cycle 1, 2, 3, 4, 5, 6
Ubiquitin mediated proteolysis 3, 4, 5
Pyrimidine metabolism 1, 3, 5
DNA polymerase 1, 3, 5
p53 signaling pathway 3, 5
Chronic myeloid leukemia 4
N-Glycan biosynthesis 3
Biosynthesis of steroids 2
Each number indicates one of six E2F4 motifs, assigned to a KEGG
pathway category.
3568 Nucleic Acids Research, 2011,Vol.39, No. 9overexpression of E2F4 and RBL2 or E2F4 and DP-1
caused the down-regulation of more E2F4 target genes
than overexpression of E2F4 alone. However,
co-expression of E2F4 and DP-1 also activated several
genes. K-means clustering revealed four distinct clusters
of genes whose expression was signiﬁcantly altered: genes
activated by overexpression of E2F4+DP-1 (cluster I),
genes repressed by overexpression of E2F4+DP-1
(cluster II), genes activated by E2F4 alone (cluster III)
and genes repressed by E2F4+RBL2 (cluster IV)
(Figure 5C). Cell cycle genes were highly enriched in
both clusters I and IV. Cluster I contained DNA replica-
tion and repair genes, while response to endogenous
stimulus and programmed cell death were categories
enriched in cluster III. These results indicate that E2F4
can function as either an activator or a repressor of tran-
scription, and is involved in diverse physiological
processes. More importantly, several genes whose expres-
sion is positively associated with cell cycle progression
were activated by E2F4 and its cofactors overexpression
(CDC6, CDCA5, CEP55, MYBL2, RPA1, SGOL2 and
SMC3). Only a subset of E2F4 binding targets showed
signiﬁcant expression changes, which suggests that the
regulation of E2F4 target genes may be more complex
than currently perceived. Interestingly, even the
low-scoring ChIP-seq binding targets were just as likely
to be differentially expressed as the high-scoring
ChIP-seq targets, and are therefore likely to be just as
biologically meaningful (Supplementary Figure S5).
E2F4 can regulate microRNAs
miRNAs have been implicated in ﬁne tuning gene expres-
sion by cleaving target mRNAs or inhibiting their trans-
lation, and some of them cooperate to regulate speciﬁc
cellular events (40–42). The expression of miRNAs is
modulated by TFs and reciprocally, TFs are also
regulated by miRNAs (43–45). To address whether
E2F4 potentially regulates miRNAs, we ﬁrst compared
E2F4 binding sites with predicted human miRNA pro-
moters that were identiﬁed based on histone modiﬁcation
signatures (46) and found 41 putative miRNA targets of
E2F4 (Supplementary Table S12). Since miRNA pro-
moters are not well-deﬁned, we also examined E2F4
binding sites located within 10kb upstream of mature
miRNA coding sequences. For this latter analysis, we
excluded miRNAs present within exonic or intronic
regions as it was not possible to assign E2F4 binding
sites unambiguously to the miRNA or its parent gene.
We thus identiﬁed an additional 161 miRNAs that
showed E2F4 binding within 10kb upstream of their
coding regions (Supplementary Table S13). E2F4
showed strong binding to the putative promoters of the
mir-17-92 cluster and let-7a, which are highly conserved
miRNAs, as well as miR-22, an exonic miRNA
(Figure 6A and Supplementary Figure S6). Quantitative
ChIP-PCR conﬁrmed that E2F4 was indeed recruited to
these three miRNA promoters in lymphoblastoid cells
(Figure 6B). To investigate whether E2F4, either by
itself or in combination with its cofactors, could regulate
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Figure 5. Overexpression of E2F4 and its cofactors (DP-1 and RBL2).
(A) qPCR veriﬁcation of increase in mRNA of E2F4 and its cofactors.
GAPDH was used as an internal control and the log-scaled y-axis
shows the fold increase of the indicated mRNA relative to the empty
vector control. (B) Western blotting conﬁrming overexpression of E2F4
and its cofactors at the protein level. Empty vector was used as a
control. (C) K-means clustering of E2F4 targets identiﬁed by
ChIP-seq along with gene expression data obtained in four different
overexpression conditions. The data plotted is the expression value
relative to that of a vehicle transfection control. The signiﬁcance
value (X) obtained from error model analysis was used for the cluster-
ing. A signiﬁcance value of 3.3 corresponds to a P-value of 0.001. ChIP
score was transformed to natural log.
Table 3. Number of up- or down-regulated genes after overexpression
of E2F4 and its cofactors
(P<0.001) Number of expression-changed genes
Overexpression Up-regulated Down-regulated
E2F4 167 128
E2F4+DP-1 314 341
E2F4+RBL 105 171
E2F4+DP-1+RBL2 228 281
P-value was calculated using an error model (24)
Nucleic Acids Research,2011, Vol.39, No. 9 3569these miRNAs, we ﬁrst established that E2F4 did bind to
the promoters of these miRNAs in HeLa cells also
(Figure 6B). We then used a quantitative TaqMan
qPCR assay to measure expression changes of those
three miRNAs in response to overexpression of E2F4
and its cofactors. All three miRNAs showed modest
down-regulation upon overexpression of E2F4 alone or
in combination with its cofactors (Figure 6C).
DISCUSSION
The 16246 E2F4 binding sites in the human genome that
we identiﬁed by ChIP-seq are consistent with the number
estimated by extrapolation from the sites previously
identiﬁed using tiling microarrays covering 1% of the
human genome (187 sites) (16). While this manuscript
was in preparation, another study reported identiﬁcation
of  15000 E2F4 binding sites in K562 erythroleukemia
cells (47). Despite the different cell lines used, we noted
that 54% of the binding sites we identiﬁed overlapped sites
identiﬁed by this independent study.
About 56% of E2F4 sites in our study were found at
promoters, and the average binding proﬁle of E2F4
relative to a gene showed a preference of E2F4 to bind
near the TSS. This ﬁnding also agrees with previously
published E2F4 ChIP-chip data (16). Overall, our E2F4
binding site analysis suggests that E2F4 mainly regulates
the expression of target genes by being recruited to their
core promoters. However, our unbiased ChIP-seq
approach revealed a signiﬁcant proportion of distal
E2F4 sites that have not been noted before. This implies
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Figure 6. E2F4 can regulate miRNAs. (A) ChIP-seq data showing E2F4 binding within 10kb upstream of the mir-17–92 cluster. The positions of the
miRNAs are shown in red. The bottom track shows phylogenetic conservation across vertebrates species (Vertebrate Multiz Alignment & PhastCons
Conservation: http://genome.ucsc.edu) with darker vertical bars indicating greater conservation. (B) qPCR veriﬁcation of E2F4 binding sites
upstream of indicated miRNAs in lymphoblastoid and HeLa cells. (C) TaqMan qPCR data for miRNA expression upon overexpression of E2F4
and its cofactors. Different combinations of E2F4 overexpression with its cofactors caused a modest decrease in the expression of all three miRNAs.
The data plotted is the log2 of the expression relative to RNU66 which served as the internal control.
3570 Nucleic Acids Research, 2011,Vol.39, No. 9that in addition to regulating target genes by binding to
the core promoter, E2F4 may be involved in additional
modes of gene regulation. Many TF binding sites in eu-
karyotes occur far away from TSSs and these distal regu-
latory regions are believed to have important
physiological roles (48,49). For instance, a TF can play
diverse roles by interacting with different cis-regulatory
elements such as enhancers, insulators, or silencers. It is
reasonable to speculate that some distal E2F4 binding
sites function as enhancers or silencers to modulate
target gene expression. Half of the distal E2F4 sites
showed histone modiﬁcation signatures characteristic of
enhancers, suggesting that E2F4 may act like an
enhancer at speciﬁc loci. Based on luciferase reporter
gene assays we conﬁrmed that some of our distal E2F4
sites can function as enhancers. However, 5 out of 10
distal E2F4 binding sites did not show enhancer activity
in the luciferase reporter assays even though those sites
were highly enriched with enhancer marks of histone
and p300 binding. This discrepancy may be in part
because enhancers are cell-type speciﬁc, and the histone
modiﬁcation data were generated in a different cell type
from the ChIP-seq data, and in part because histone modi-
ﬁcations are not sufﬁcient to fully specify enhancers.
Nonetheless, our study suggests that in addition to a
role at core promoters, E2F4 may act as a long-range
regulator.
We found that E2F4 binding sites were highly enriched
in bidirectional promoters, which is consistent with previ-
ously published data (31). Bidirectional promoters may be
an efﬁcient way to modulate gene expression where the
same DNA element regulates two different downstream
genes at the same time. Genome-wide studies of bidirec-
tional promoters in several mammalian genomes have
suggested that they are evolutionarily conserved and func-
tionally related in certain categories like DNA repair
(32,33). We also found that E2F4 can modulate most
E2F family members, as well as its own cofactors.
Comparing our E2F4 target genes with all known RBL1
and RBL2 targets revealed that almost all cofactor targets
overlapped with E2F4 targets. A number of studies have
shown that E2F promoter speciﬁcity is determined by its
cofactors. For instance, E2F4-p130/RBL2 is a major
complex in quiescent cells, whereas an E2F4-pRB
or –p170/RBL1 complex is important in the G1 phase of
the cell cycle, which suggests distinct roles of cofactors in
different cell cycle stages (50,51). The facts that E2F4
binds and may directly regulate its cofactors and fam-
ily members suggest the possibility of feedback loops
where the activity of E2F4 can be potentiated. Motif
analysis revealed that the canonical E2F4 motif was
present in only 5% of the 16246 E2F4 binding sites.
This result implies the possibility that E2F4 uses other
unknown motifs or is recruited to target promoters
by the aid of other cofactors. De novo motif analysis
using DRIM discovered ﬁve putative novel motifs. All
motifs were found to be positioned near the peak of the
ChIP-seq signal. As a corollary, this suggests that the
peak position identiﬁed by our algorithm from ChIP-seq
read data denotes the actual binding site of the
protein. This level of resolution has not been achieved
before in previous studies of E2F4 binding since they all
used lower resolution tiling array approaches to identify
binding sites.
Pathway analysis suggested that all E2F4 motifs were
likely used to regulate the cell cycle pathway. Speciﬁcally,
motif 1 (RTTYGAA) which was similar to a cell cycle
repressor element, CHR (cell-cycle homology region; TT
GAA) where E2F4/RB complexes were recruited (52,53),
was highly enriched only among cell cycle pathway genes.
Co-enrichment analysis identiﬁed several TFs that may
co-regulate genes with E2F4. For example, many E2F4
targets such as E2F1, b-MYB and HSORC1 contain
SP1 motifs near E2F binding sites (54); MYB and YY1
are known to be transcriptional partners of several E2F
proteins (55–57); the constitutively expressed factor,
NF-Y, binds to several cell cycle related E2F target pro-
moters, and helps other regulatory proteins (PCAF and
p300) gain access to target promoters to activate down-
stream genes (58).
E2F4 was classiﬁed as a repressor of cell proliferation
because it binds to its target promoters involved in cell
cycle progression in G0/G1 and represses them. Even
though E2F4 was previously known as a repressor, some
studies introduced the possibility that E2F4 may function
as an activator by showing that it was able to trigger cell
proliferation. In addition, overexpression of E2F4 in
transgenic mice induced cell propagation in the basal
layer of the epidermis (59,60). Our genome-wide identiﬁ-
cation of E2F4 binding targets and transient perturbation
of E2F4 followed by gene expression proﬁling indicate
that E2F4 can indeed function as either an activator or
a repressor of transcription. In particular, cluster I, con-
sisting of genes activated by E2F4 and DP-1, contains
genes implicated in positive regulation of the cell cycle,
suggesting that E2F4 may function as a cell cycle activa-
tor. Our data further revealed that E2F4 is capable of
repressing the expression of several miRNAs such as the
mir-17–92 cluster, mir-22, and let-7a, albeit by modest
amounts. The mir-17–92 cluster, encoding six miRNAs,
is known to be regulated by MYC, E2F1 and E2F3, and
this regulation promotes cell proliferation (44,61,62).
E2F4 may mediate its anti-proliferative role partly by re-
pressing the mir-17-92 cluster. E2F4 is not only capable of
repressing the expression of E2F1–E2F3, thus indirectly
down-regulating the mir-17–92 cluster, but also binds to
the mir-17–92 cluster promoter and directly regulates it,
suggesting that it mediates a feedback loop for the regu-
lation of the miR-17–92 cluster. Another miRNA target of
E2F4, let-7a, is able to down-regulate the expression of
MYC as well as trigger cell cycle arrest (45). Thus, E2F4
can not only regulate the expression of MYC directly (63),
but also indirectly via let-7a, suggestive of another regu-
latory feedback loop. In summary, our genome-wide E2F4
target analysis reveals diverse functions of E2F4 and
provides support for E2F4 functioning both as a
long-range transcriptional regulators of mRNAs as well
as a miRNA regulator, which allowed us to gain insights
into understanding the versatile roles of this member of
the E2F family.
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